BioPorto

Share Issue/Capital Change • Aug 31, 2015

August 31, 2015, The Board of Directors of BioPorto A/S (BioPorto) decided to
partially exercise the authorization in the Company Articles article 16b to
make a direct placement to a limited number of institutional and financial
investors. Implementation of the issue has been finally adopted by the board
today.

The issue was fully subscribed, and the Board has decided to issue 11,724,750
new shares at DKK 1 each, against payment of DKK 2.40 per share at DKK 1.00.
The subscription price of DKK 2.40 was calculated as the weighted average price
of the share at Nasdaq Copenhagen over the past ten trading days prior to
August 31, 2015.

The total proceeds from the share issue amounts to DKK 28.1 million, from which
transaction costs be deducted. Net proceeds amount to 26.6 million.

The new shares are equivalent to 9,9% of BioPorto’s registered share capital
before the capital increase and the share issue is exempt from prospectus
requirements.

The new shares have the same rights as the existing shares. The new shares are
entitled to dividend from the time when the capital increase is registered with
the Danish Business Authority. The capital increase is expected to be
registered on September 4, 2015. The new shares are expected to trade on the
Nasdaq Copenhagen as soon as possible thereafter.

Following the registration of the 11,724,750 new shares of DKK 1.00, BioPorto’s
nominal share capital amounts to DKK 129,598,960 consisting of 129,598,960
shares of DKK 1.00.

Part of the net proceeds are expected to be used for establishing a business
platform in the USA, which will include BioPorto’s own US sales and support
organization in charge of the commercialization of The NGAL Test™ when FDA
approval is expectedly achieved in early 2016. Part of the proceeds are
expected to be used to complete the development and marketing of the new
products gRAD and immunodeficiency tests as well as other projects.

Peter Mørch Eriksen, CEO, comments: "I am very pleased with the fully
subscribed issue, in which we welcome new institutional investors, and secure
the capital to get a good start in the USA. It provides both energy and
resources to continue the important work towards the next milestones for the
company. "

For further information, please contact:

Peter Mørch Eriksen, CEO

Telephone +45 4529 0000, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the Nasdaq Copenhagen stock exchange.